Importance of Cross-Functional Review in Change Control Systems

Introduction to the Audit Finding

1. What Was Observed?

The change control process lacked a defined cross-functional review mechanism. Changes were initiated and approved within a single department without input from impacted teams.

2. Why This Is a Compliance Risk

• Unassessed impact on quality, validation, regulatory filings, and training
• Increased chance of implementation errors
• Failure to identify downstream risks in other functions

3. GMP Context

This finding reflects a failure to recognize change control as a multi-departmental responsibility essential for maintaining a robust GMP compliance framework.

Regulatory Expectations and Inspection Observations

1. 21 CFR 211.100(a)

Requires thorough review and approval of changes to procedures with an emphasis on quality impact assessment.

2. EU GMP Chapter 1

Highlights the need for coordinated quality management and proper documentation of roles in decision-making.

3. WHO GMP

Change control must be systematically evaluated by all impacted stakeholders.

4. Example Observations

• FDA: “Change #1123 lacked documented review by QA, validation, and regulatory functions.”
• MHRA: “Systemic issue where change controls are closed without cross-functional assessment.”

Root Causes of Missing Cross-Functional Review

1. Siloed Departmental Culture

Departments initiate and approve changes without communication with other stakeholders.

2. Poorly Designed Change Forms

No fields or steps exist to record reviews by other functional areas.

3. Inadequate SOPs

Current SOPs do not mandate review or signoff from QA, validation, regulatory, or production.

4. Lack of Training on Impact Assessment

Change initiators are unaware of how their modifications affect broader operations.

Prevention of Review Gaps in Change Control

1. SOP Revision for Functional Review

• Define minimum required reviewers for different change types
• Include RACI matrix in change control SOP

2. Standardized Change Templates

Introduce forms with mandatory reviewer sign-off fields for QA, Regulatory Affairs, Production, and Validation.

3. Cross-Functional Change Control Team

Form a permanent review team including department heads or designated reviewers for changes involving quality, process, or regulatory impact.

4. Electronic QMS Integration

Use change workflows that auto-assign reviewers and prevent closure without their approval.

5. Training and Governance

Reinforce training through examples from Stability Studies where change implementation failed due to missed cross-functional alignment.

Corrective and Preventive Actions (CAPA)

1. Immediate Corrective Actions

• Review all open and recent change controls for missing cross-functional input
• Require retrospective assessments where reviewers were omitted
• Delay implementation of unreviewed changes pending formal approval

2. Preventive Actions

• Amend SOPs to include multi-functional review for every change category
• Link each change to associated risk assessments and validation protocols
• Include change impact reviews in QA internal audits

3. Governance & Monitoring

Implement dashboards and KPIs to monitor % of changes reviewed cross-functionally. Establish escalation protocols for missed reviews.

4. Regulatory Framework Support

Align internal review processes with agency expectations such as CDSCO and USFDA guidelines for pharmaceutical change management.